KNSA — Kiniksa Pharmaceuticals International, plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1730430 ·
United Kingdom
Last close
$95.11
Market Cap
$4.64B
52W High
$99.31
52W Low
$37.02
ADV30
824,335
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 285,970,000 | 152,383,000 | 54,236,000 | 47,345,000 | 983,243,000 | 81,660,000 | 273,050,000 |
| Jun 2026 | 243,600,000 | 131,959,000 | 27,194,000 | 25,432,000 | 896,110,000 | 175,677,000 | 241,961,000 |
| Mar 2026 | 214,266,000 | 117,893,000 | 29,267,000 | 22,592,000 | 825,280,000 | 189,952,000 | 219,593,000 |
| Dec 2025 | 202,127,000 | 111,152,000 | 19,768,000 | 14,199,000 | 763,633,000 | 165,596,000 | 196,027,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$198,835,000
Investing CF
$-314,874,000
Financing CF
$22,841,000
CapEx
$-1,637,000
Dividends Paid
—
Buybacks
$-15,777,000
EPS Diluted TTM
$1.30
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-366,769,000
Inventory
$108,028,000
Receivables
$30,779,000
ST Investments
$487,098,000
EBIT TTM
$130,465,000
Pretax Income TTM
$146,152,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$945,963,008
EBITDA
$132,362,000
Free Cash Flow
$135,869,632
Enterprise Value
$6,686,580,224
Total Cash
$568,758,016
Total Debt
$7,884,000
Shares Out
48,836,965
Trailing EPS
$1.32
Book Value
$9.05
ROE
17.6%
ROA
9.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 677,564,000 | 77,221,000 | 59,005,000 | 763,633,000 | 196,027,000 | 567,606,000 | 137,985,000 |
| Dec 2024 | 423,239,000 | -45,616,000 | -43,193,000 | 580,553,000 | 142,117,000 | 438,436,000 | 25,689,000 |
| Dec 2023 | 270,259,000 | -25,196,000 | 14,084,000 | 526,322,000 | 87,483,000 | 438,839,000 | 13,301,000 |
| Dec 2022 | 220,180,000 | 9,773,000 | 183,363,000 | 459,672,000 | 63,523,000 | 396,149,000 | 5,807,000 |
TTM Snapshot
Revenues TTM
$840,848,000
NetIncome TTM
$80,658,000
OpCashFlow TTM
—
Assets (Latest)
$896,110,000
Forward EPS
$2.18
Max Pain — expiry 2026-12-18
max pain strike: $75.00 · spot: $95.05 · call oi: 2,205 · put oi: 414
Expected Move to 2026-12-18:
±$11.25
(11.84%) —
implied range
$83.80 –
$106.30
· ATM straddle on $95.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | $4.60B | $42.04 | — |
| GIKLY | Grifols SA | $4.69B | $5.55 | — |
| IONS | IONIS PHARMACEUTICALS INC | $4.49B | $26.96 | — |
| COGT | Cogent Biosciences, Inc. | $4.85B | $27.85 | — |
| ERAS | Erasca, Inc. | $4.87B | $13.89 | — |
News headlines (Yahoo Finance, 1h cache)
Top pharma stock to watch: TD Cowen’s pick
2026-11-18 20:20 · Yahoo
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
2026-11-11 21:01 · Yahoo
Kiniksa (KNSA) Stock Jumps As Q3 Results Fuel Growth Debate
2026-10-28 07:11 · Yahoo
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
2026-10-27 18:11 · Yahoo
Kiniksa (KNSA) Q3 2026 Earnings Call Transcript
2026-10-27 16:43 · Yahoo
What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
2026-10-27 16:04 · Yahoo
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
2026-10-27 11:50 · Yahoo
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
2026-10-27 11:30 · Yahoo
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
2026-10-22 20:01 · Yahoo
Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight
2026-10-14 20:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.